Glycopyrrolate topical - Dermira

Drug Profile

Glycopyrrolate topical - Dermira

Alternative Names: DRM-04B; DRM04; Glycopyrronium tosylate; Glycopyrronium tosylate hydrate; Glycopyrronium tosylate monohydrate

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stiefel Laboratories
  • Developer Dermira
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Hyperhidrosis

Most Recent Events

  • 06 Nov 2017 Preregistration for Hyperhidrosis (In adults, In adolescents) in USA (Topical)
  • 06 Nov 2017 Dermira announces intention to market glycopyrrolate for the treatment of Hyperhidrosis in the second half of 2018
  • 06 Nov 2017 FDA assigns PDUFA action date of 30/06/2018 for glycopyrrolate for Hyperhidrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top